ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Carrick Therapeutics, a Dublin-based cancer therapy developer, has raised $35 million from Pfizer and $25 million in series C financing from other investors. Pfizer’s investment will support development of samuraciclib, a drug candidate for breast cancer. Pfizer will help Carrick with its Phase 2 study of the small molecule in combination with fulvestrant to treat HR+, HER2– advanced breast cancer that is resistant to another class of medicines. Samuraciclib is also being evaluated for use in prostate cancer, the companies say.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter